BioGenex

Krishan Kalra is the CEO of BioGenex. To contact Krishan Kalra email at [email protected].

The decision makers in BioGenex are Avijit Paul, Rajesh Shah, Jintao Chen, etc. Click to Find BioGenex decision makers emails.

BioGenex specializes in advanced fully-automated molecular pathology systems designed for cancer diagnosis, prognosis, and personalized medicine. Our systems include solutions for immunohistochemistry (IHC), in situ hybridization (ISH), and molecular diagnostics, ensuring high-quality results for life science research and clinical applications.

Yes, BioGenex's advanced molecular pathology systems are specifically designed to support personalized medicine initiatives. Our solutions enable precise cancer diagnosis and prognosis by providing detailed insights into the molecular characteristics of tumors, allowing healthcare providers to tailor treatment plans based on individual patient profiles.

The eFISHency integrated workflow solution is BioGenex's latest offering that streamlines the process of performing fluorescence in situ hybridization (FISH) assays. This fully automated system enhances efficiency and accuracy in detecting genetic abnormalities associated with various cancers, ultimately improving diagnostic outcomes.

BioGenex serves a variety of industries, including clinical laboratories, research institutions, and pharmaceutical companies. Our products are utilized in cancer research, diagnostics, and drug development, providing essential tools for pathologists and researchers in their quest for better patient outcomes.

BioGenex offers a comprehensive range of reagents and antibodies tailored for immunohistochemistry (IHC) and in situ hybridization (ISH) applications. Our high-quality reagents are designed to ensure optimal performance in various assays, enabling researchers and clinicians to achieve reliable and reproducible results.

BioGenex is committed to maintaining the highest standards of quality and reliability in our products. We adhere to stringent quality control processes and regulatory compliance, including ISO certification and CE marking for our in vitro diagnostic (IVD) products. Continuous innovation and rigorous testing ensure that our systems and reagents meet the needs of our customers in the molecular pathology field.